Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease
|
|
- Veronica Primrose Lambert
- 6 years ago
- Views:
Transcription
1 REGULAR ARTICLE Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease David Calvet, 1 Titien Tuilier, 2 Nicolas Mélé, 1 Guillaume Turc, 1 Anoosha Habibi, 3 Nassim Ait Abdallah, 3 Loubna Majhadi, 4 François Hemery, 5 Myriam Edjlali, 6 Frédéric Galacteros, 3 and Pablo Bartolucci 3 1 Service de Neurologie, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Département Hospitalo-Universitaire (DHU) Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France; 2 Service de Neuroradiologie, Hôpital Henri-Mondor, Université Paris-Est Créteil (UPEC), Créteil, France; 3 Sickle Cell Referral Center, Service de Médecine Interne, Hôpital Henri-Mondor (Assistance Publique Hôpitaux de Paris [APHP]), UPEC, INSERM U895, Team 2, Laboratoire d Excellence GRex, Créteil, France; 4 Service de Neurologie, Hôpital Henri-Mondor, UPEC, Créteil, France; 5 Département Informatique Médicale, Hôpital Henri-Mondor (APHP), Créteil, France; and 6 Service de Neuroradiologie, Centre Hospitalier Sainte-Anne, Université Paris Descartes, DHU Neurovasc Sorbonne Paris Cité, INSERM U894, Paris, France Key Points Low %HbF is independently associated with silent WMCs on brain imaging in adults with SCD. Our results highlight the potential use of therapeutic strategies inducing HbF expression in SCD patients with silent white matter changes. Silent white matter changes (WMCs) on brain imaging are common in individuals with sickle cell disease (SCD) and are associated with cognitive deficits in children. We investigated the factors predictive of WMCs in adults with homozygous SCD and no history of neurological conditions. Patients were recruited from a cohort of adults with homozygous SCD followed up at an adult sickle cell referral center for which steady-state measurements of biological parameters and magnetic resonance imaging scans of the brain were available. WMCs were rated by consensus, on a validated age-related WMC scale. The prevalence of WMCs was 49% (95% confidence interval [CI], 39%-60%) in the 83 patients without vasculopathy included. In univariable analysis, the patients who had WMCs were more likely to be older (P 5.003) and to have hypertension (P 5.02), a lower mean corpuscular volume (P 5.005), a lower corpuscular hemoglobin concentration (P 5.008), and a lower fetal hemoglobin percentage (%HbF) (P 5.003). In multivariable analysis, only a lower %HbF remained associated with the presence of WMCs (odds ratio [OR] per 1% increase in %HbF, 0.84; 95% CI, ; P 5.021). %HbF was also associated with WMC burden (P for trend 5.007). Multivariable ordinal logistic regression showed an inverse relationship between WMC burden (age-related WMC score divided into 4 strata) and HbF level (OR for 1% increase in %HbF, 0.89; 95% CI, ; P 5.039). Our study suggests that HbF may protect against silent WMCs, decreasing the likelihood of WMCs being present and their severity. It may therefore be beneficial to increase HbF levels in patients with WMCs. Introduction Stroke is one of the leading causes of death in both children 1 and adults 2 with sickle cell disease (SCD). During the natural course of the disease, 11% of patients with homozygous SCD have a clinically overt stroke by age 20 years, and 24% by age 45 years. 3 Ischemic strokes are common in children and young adults, but the frequency of hemorrhages peaks during the third decade of life. 3 Different types of ischemic stroke are observed, but the most common subtype of overt cerebral infarction is border-zone infarcts occurring between the anterior and middle cerebral artery due to a specific large-vessel vasculopathy. 4 Blood exchange and transfusion therapy greatly decrease the risk of a first ischemic stroke in children with high-velocity blood flow detected on a Doppler scan. 5 Furthermore, white-matter changes (WMCs) on brain imaging, in patients with no overt neurological signs or history suggestive of a Submitted 3 February 2017; accepted 8 September DOI / bloodadvances by The American Society of Hematology 12 DECEMBER 2017 x VOLUME 1, NUMBER
2 cerebrovascular event, are observed in approximately one-quarter to one-third of children with homozygous SCD. 6-8 Such damage is the most frequent type of permanent neurological injury in children with homozygous SCD and, probably, also in adults. 9 WMCs are generally considered to be silent lesions, but children with SCD displaying such lesions have been found to have cognitive deficits and to be at risk of intellectual decline Most WMCs are observed in patients with no specific vasculopathy. 14 A low pain event rate, a history of seizure, high white blood cell counts, and the Senegal SEN b-globin haplotype have been identified as being associated with silent WMCs in children with SCD. 15 It has recently been shown that regular blood transfusion therapy significantly decreases the incidence or recurrence of cerebral infarcts (silent and/or overt) in children with homozygous SCD with silent WMCs on magnetic resonance imaging (MRI) scan. 16 However, the value of systematic and repeated MRI screening for such lesions in patients with SCD, and of systematic treatment with regular blood transfusion therapy, remains a matter of debate This issue is of particular concern in the growing population of adults with SCD because of the steady increase in the prevalence of silent infarcts with age. 20 The objective of this study was to identify predictors of WMCs in adults with homozygous SCD and no history of stroke or vasculopathy, focusing particularly on modifiable biological candidates. Methods Patients Patients were recruited from a cohort of adults with homozygous SCD for whom steady-state biological parameters had been recorded (n ), who were followed up at our adult sickle cell referral center. Patients are examined at least once every 6 months. Demographic data, vascular risk factors, and medical history were collected prospectively on a standardized electronic case report form. Patients older than 18 years who had no history of cerebrovascular disease, had normal results on neurological examination, had steadystate biological results recorded before hydroxyurea treatment or transfusion, and had undergone brain MRI scans in our referral hospital between January 2007 and December 2013 for screening purposes were included in the study. The decision to perform an MRI scan in our referral hospital was driven mainly by close geographic location of included patients, whereas other patients had undergone MRI scan in other private or public health institutions. Biological parameters Laboratory data were collected during routine outpatient visits. Hematological data are expressed as 2 or 3 separate steady-state determinations. Steady state was defined as a visit at least 1 month after an acute clinical event (vaso-occlusive crisis, infection, acute chest syndrome, or any other clinical event resulting in hospitalization and/or blood transfusion) before any hydroxyurea treatment and at least 3 months after blood transfusion. All laboratory analyses were performed on site, in the clinical laboratories of Henri Mondor Hospital. Biological findings were recorded prospectively in a database. The following data were extracted: blood cell count, lactate dehydrogenase levels, bilirubin concentration, and fetal hemoglobin percentage (%HbF). The levels of hemoglobin S (HbS), HbF, and hemoglobin A2 (HbA 2 ) were determined by cation-exchange highperformance liquid chromatography with a Variant hemoglobin analyzer (Variant Hemoglobin Testing System; BioRad, Hercules, CA). Three forms of deletional a-thalassemia (a 23.7, a 220.5, and Mediterranean type) were detected by polymerase chain reaction. Polymerase chain reaction restriction fragment length polymorphism was used to determine b-globin gene cluster haplotype. 21 MRI scans Patients who had undergone brain MRI scans were identified from our local prospective MRI register. All MRI scans were performed on a Magneton Verio 3-T MRI scanner (Siemens, Erlangen, Germany). Two investigators (T.T. and N.M.) trained in the analysis of WMCs and blind to clinical and biological data rated all MRI scans, specifically in the context of this study, by consensus, using the age-related WMC (ARWMC) score 22 on a dedicated workstation. White matter lesions in the cerebral hemispheres and brainstem were identified as poorly defined hyperintensities of at least 5 mm in diameter on T2-weighted or fluidattenuated inversion recovery (FLAIR) MRI scans. Changes in the basal ganglia were rated in the same manner. The extent of white matter disease was rated on a 4-point scale in different regions of the brain, on T2-weighted and FLAIR MRI scans: 0 5 no lesions (including symmetric, well-defined caps or bands); 1 5 focal lesions; 2 5 lesions beginning to become confluent; and 3 5 diffuse involvement of the entire region, with or without the involvement of U-fibers. We assessed the 5 brain regions in the left and right hemispheres separately for each patient: the frontal area (the frontal lobe anterior to the central sulcus), the parieto-occipital area (the parietal and occipital lobes together), the temporal area (the temporal lobe, with a line from the posterior part of the Sylvian fissure to the trigones of the lateral ventricles separating this area from the parieto-occipital area), the infratentorial area (including the brainstem and cerebellum), and the basal ganglion region (including the striatum, globus pallidus, thalamus, external capsules, and insula). The total ARWMC score was then obtained by adding the scores for each brain region. Thus, the total ARWMC score ranged from 0 to 30. In addition to rating brain lesions, both investigators assessed intracranial arteries on 3-dimensional time-of-flight MR angiography of the circle of Willis, to confirm the absence of irregularities or stenosis. Ethics statement In accordance with French law, this study did not require approval from an institutional review board or ethics committee, because it involved only retrospective analysis of anonymized data collected prospectively as part of routine clinical care. Statistical analysis Continuous variables are expressed as mean 6 standard deviation (SD) or median (interquartile range), and categorical variables are expressed as number (percentage). The relationships between the presence of WMCs (dependent variable, defined as present vs absent) and patient characteristics were assessed by calculating crude and adjusted odds ratios (ORs) with binary logistic regression models. Variables with values of P,.1 in univariable analysis were included in multivariable logistic models, 23 taking potential multicollinearity into account. We also assessed the associations between biological findings and severity of WMCs, analyzed as a discrete variable. To this end, we 2504 CALVET et al 12 DECEMBER 2017 x VOLUME 1, NUMBER 26
3 used Jonckheere-Terpstra tests to assess the association between each biological finding and ARWMCs. We subsequently divided ARWMC burden into 4 strata (0, 1, 2-4, and $5), the last 3 strata of which corresponded to the tertiles of patients in which ARWMCs were detected. We performed univariable and multivariable ordinal logistic regression analyses, using 4-strata ARWMCs as the dependent variable. Variables with values of P,.1 in univariable analysis were included in the multivariable ordinal logistic regression model. Values of P,.05 in 2-tailed tests were considered statistically significant. Statistical analysis was conducted with SPSS 23.0 (IBM Corporation, Armonk, NY) and SAS 9.4 (SAS Institute, Cary, NC). Results Using the database, we identified 102 patients as eligible for inclusion in our study. The included patients were similar to those for whom steady-state biological results were variable, but no MRI scan had been performed for screening purposes, in terms of age, hemoglobin levels, mean corpuscular volume, and %HbF (data not shown). Results on brain MRI scans showed motion artifacts in 5 patients, which resulted in poor image quality precluding analysis. We excluded 14 patients because of stenotic vasculopathy identified on a 3-dimensional time-of-flight MR angiographic image of the circle of Willis. The remaining 83 patients were included in the analysis. Mean age (SD) was 43.3 (9.8) years, and 50 (60%) of the patients were female. The patients originated from the West Indies (36%), West Africa (34%), Central Africa (29%), and North Africa (1%). The demographic characteristics of the population are presented in Table 1. MRI results The prevalence of WMCs in the 83 included patients was 49% (95% confidence interval, 39%-60%). ARWMC score was calculated for these41patients.thearwmcscorewas1in15patients,2to4in 12 patients, and 5 or greater in 12 patients. The lesions were focal in 49% (20/41) of patients, and the remaining patients had either lesions in several distinct brain areas or several lesions in a single area that were beginning to become confluent. None of the patients had more severe lesions. WMCs were localized to the frontal area in 32 (78%) of 41 patients, the parieto-occipital area in 19 (46%) of 41 patients, thetemporalareain3(7%)of41patients,thebasalganglionregionin 7 (17%) of 41 patients, and the infratentorial area in 3 (7%) of 41 patients (Figure 1). Table 2 shows biological findings for the population according to the presence or absence of WMCs. b-globin gene haplotype was known for 70 patients (84%). Homozygosity for the Benin BEN b-globin haplotype was identified in 22 patients (31%), homozygosity for the Bantu CAR b-globin haplotype was found in 22 patients (31%), and homozygosity for the SEN b-globin haplotype was detected in 10 patients (14%). Other patients had heterozygous b-globin haplotypes. Status of a-globin thalassemia deletion was available for 67 patients (82%), 33 (49%) of whom had no deletion, 30 (45%) of whom had 1 a 23.7 deletion, 2 (3%) of whom had 2 a 23.7 deletions, and 2 (3%) of whom had a triplication of the a-globin gene. Factors associated with the presence of WMCs In univariable analysis (Table 2), patients with WMCs were more likely to be older (P 5.03) and to have hypertension (P 5.02), a lower mean corpuscular volume (P 5.005), a lower Table 1. Characteristics of the population Values Mean age 6 SD, y Female 50 (60) Ethnic origin West Indies 30 (36) West Africa 28 (34) Central Africa 24 (29) North Africa 1 (1) Hypertension* 10 (12) Diabetes mellitus 2(2) Active smoking status 5 (6) Treated dyslipidemia 1 (1) Headache 13 (16) Values are n (%), unless otherwise indicated. *Known (treated or not). Hypertension was defined as a systolic blood pressure.140 mm Hg and/or a diastolic blood pressure.90 mm Hg. Treated or not. corpuscular hemoglobin concentration (P 5.008), and a lower %HbF (P 5.003). Because of the strong correlation between corpuscular volume and corpuscular hemoglobin concentration (Spearman r ; P,.0001), we included only corpuscular volume in the multivariable model to prevent multicollinearity. In this multivariable analysis (Table 3), only a lower %HbF remained independently associated with the presence of WMCs. Mean (SD) A g/g g ratio, available for 56 patients (67%), was 1.1 (0.49). Median (interquartile range) %HbF was 10.0% (4.6%- 16.2%) in patients homozygous for the SEN b-globin haplotype and 6.0% (2.9%-11.1%) in patients homozygous for the CAR b-globin haplotype. The association between a lower %HbF and the presence of WMCs remained significant after adjustment for b-globin haplotype in the 70 patients for whom b-globin haplotype was known. In a post hoc sensitivity analysis conducted after exclusion of the 14 patients (17%) who started receiving hydroxyurea after steady-state measurement of biological parameters but before MRI scans, the association betweenalower%hbfandthepresenceofwmcswassimilar. Factors associated with WMC burden The %HbF was associated with ARWMC score (Jonckheere-Terpstra test, P for trend 5.007). Univariable ordinal logistic regression analysis also revealed an inverse relationship between WMC burden (ARWMC score divided into 4 strata) and %HbF (OR for 1% increase in fetal hemoglobin, 0.87; 95% CI, ; P 5.006). This association remained significant (OR for 1% increase in fetal hemoglobin, 0.89; 95% CI, ; P 5.039) after adjustment for age, hypertension, and mean corpuscular volume (Table 4). Discussion Our study shows that a low %HbF is associated with both the presence and burden of silent WMCs, with a 13% relative decrease in the prevalence of WMCs per 1% increase in HbF concentration among adult patients with homozygous SCD, normal results on neurological examination, no history of cerebrovascular disease, and no disease-specific vasculopathy. 12 DECEMBER 2017 x VOLUME 1, NUMBER 26 BRAIN LESIONS IN ADULTS WITH HOMOZYGOUS SCD 2505
4 A B C Figure 1. MRI, FLAIR images, axial slices. (A) White matter lesion, type 1: focal lesion. Focal hypersignal on right frontal lobe. (B) White matter lesion, type 2: beginning confluence lesion. Multiple focal hypersignal on right and left hemispheres. (C) Another white matter lesion, type 2: beginning confluence lesion. Multiple hypersignal on right and left hemispheres with small confluence. The prevalence of WMCs in our cohort of adults (49%) was higher than that reported for cohorts of children, 8,15,20,24-27 but it was highly consistent with the findings of a recent study reporting a prevalence of silent infarcts of 53% in a cohort of adult patients with SCD with a median age of 30 years. 28 However, caution is required when studies are compared directly because of differences among studies in definitions; brain imaging techniques; and population characteristics, particularly concerning cerebrovascular history. A steady increase in the prevalence of brain lesions with age was clearly demonstrated in children, in a recent study by Bernaudin et al. 24 The cumulative risk of silent cerebral infarcts was found to increase from 19.2% at age 8 years, to 32.4% at age 14 years and 39.1% at age 18 years. In our study, the most common location of WMCs was the frontal area, and half of the patients had focal lesions only, which were consistent with findings with pediatric cohorts. 29 Beyond the term silent, which simply indicates the absence of a history of stroke, children who have silent brain lesions on brain MRI scans have been shown to have poorer cognitive function than do children who have normal brain MRI findings. Indeed, in children with SCD, such silent lesions have been shown to be associated with a mean decrease in full-scale IQ of 5 points, 30 poor academic performance, 31 and a higher risk of overt strokes. 32 Table 2. Relationship between patients and the biological characteristics and (a) presence of silent WMCs and (b) WMC burden (univariable analysis) Silent WMCs Yes (n 5 41) No (n 5 42) (a) P (b) P Age, y (11.26) (7.44) Headache, n (%) 6 (15) 7 (17) Hypertension, n (%) 9 (22) 1 (2) Smoking, n (%) 3 (7) 2 (5) White blood cell count, /L (2.23) (1.97) Red blood cell count, /L 2.84 (0.62) 2.69 (0.51) Hemoglobin, g/l 8.34 (1.16) 8.66 (1.26) Hematocrit, % (3.80) (4.06) Mean corpuscular volume, fl (9.15) (9.16), Mean corpuscular hemoglobin concentration, g/dl (3.44) (3.46), Reticulocyte count, /L (84.37) (97.53) Platelet count, /L (99.71) (97.82) Lactate dehydrogenase, U/L (193.96) (165.01) Bilirubin, mmol/l (30.25) (28.15) %HbF 5.57 (4.14) 9.46 (5.93),.01,.01 Values are mean (6 SD), unless otherwise indicated CALVET et al 12 DECEMBER 2017 x VOLUME 1, NUMBER 26
5 Table 3. Risk factors for the presence of silent WMCs (multivariable binary logistic regression analysis) Risk factors Adjusted OR (95% CI) P Age* 1.40 ( ).31 Hypertension 8.24 ( ).11 Mean corpuscular volume 0.97 ( ).34 Platelet count 1.00 ( ).29 %HbF 0.84 ( ).02 *Per 10-year increase. Per 1-point increase. Table 4. Risk factors for silent WMC burden (multivariable ordinal logistic regression analysis) Risk factors Adjusted OR (95% CI) P Age* 1.55 ( ).09 Hypertension 2.24 ( ).27 Mean corpuscular volume 0.99 ( ).68 %HbF 0.89 ( ).04 Proportional odds assumption for the model: P *Per 10-year increase. Per 1-point increase. Per 1% increase. In this cross-sectional study, it was not possible to determine when, during the patients lifetime, the WMCs had appeared. It is highly likely that a significant proportion of the cases of WMCs in our population dated from childhood. In contrast to previous studies, our study strongly suggests an association between %HbF and the presence and burden of silent WMCs. One explanation for the difference between our results and those of other studies is that previous studies in children have often taken %HbF results obtained very early in life, before the stabilization of this percentage, into account. 33 HbF is known to be the major protective factor against HbS polymerization. 34,35 Indeed, HbF contributes to formation of the a 2 b s g hybrid, which impedes HbS polymer elongation. Many studies have shown %HbF levels to be associated with clinical and/or biological protective effects. 2,36 The association between %HbF and the presence and burden of WMCs described here is highly consistent with the known antipolymerization dose-response effect of %HbF. 35,37 The lack of a protective effect of the SEN haplotype on the presence of WMCs despite a higher %HbF is consistent with the lack of a protective effect of this haplotype against silent infarcts in children reported in a previous study. 15 Haplotypes are of interest more because of their geographic origin than as a causal explanation. It is possible that deleterious polymorphisms of other genes in people from Senegal offset the beneficial effects of HbF, accounting for this paradoxical result. Another difference between our findings and those from cohorts of children is the lack of association of hemoglobin concentration with WMCs in our adult population of patients with SCD. This association was also reported in patients with end-stage renal disease 38 and thalassemia intermedia. 39,40 In adults with SCD, anemia is closely associated with hemolysis 41 and with dense, dehydrated red blood cells. 42 Our findings are not consistent with an association between WMC lesions and the hemolytic phenotype. Our study had several potential limitations. First, we could not exclude the possibility that selection bias affected the prevalence of silent WMCs obtained here. Only a few patients meeting the other inclusion criteria had undergone an MRI scan for screening purposes during the study period. However, the included patients were similar to patients for whom steady-state biological results were available but for whom no screening MRI scan had been performed, in terms of baseline characteristics and biological results. The inclusion of patients with no history of cerebrovascular disease and normal results on neurological examination only may have resulted in an underestimation of the prevalence of silent WMCs, but our results were consistent with a previous study that was conducted in adults. 28 Such potential selection biases may have affected the estimated prevalence of silent WMCs, but this would be unlikely to have any major effect on the relative effects of HbF level. However, the generalizability of our results might have been affected by the proportion of patients who had undergone an MRI. Second, hypertension, a well-known predictive factor for WMCs in the general population, 43 was not associated with silent WMCs in our cohort of adult patients with SCD. However, this absence of association was probably attributed to low statistical power, as suggested by the strong, but nonsignificant, relative effect of hypertension on the presence of WMCs in our study, because of the small sample size and the low prevalence of hypertension in such a cohort of SCD patients, as previously reported. 44 Our study has clinical implications. Indeed, increasing HbF levels through drug treatments or gene therapy is one of the current goals of SCD research. Hydroxyurea is the most widely used drug for increasing HbF levels. Many studies have shown this drug to be effective for preventing vaso-occlusive crisis and acute chest syndrome, 45 secondary cerebral vasculopathy, 46,47 and death. 48,49 Our study therefore suggests that treatment with hydroxyurea may be beneficial in patients with SCD in order to prevent WMCs. This study provides new insight into the potential protective effect of fetal hemoglobin against silent WMCs in adult patients with SCD. Further studies are required to confirm this association before hydroxyurea can be considered as a suitable treatment of increasing HbF levels to protect against WMC burden and associated cognitive disorders. Authorship Contribution: D.C. and P.B. originated the idea for the study; D.C., T.T., N.M., and P.B. contributed to the design of the study; D.C., G.T., and P.B. analyzed the data; D.C. wrote the first draft of the manuscript; and D.C., T.T., N.M., G.T., A.H., N.A.A., L.M., F.H., M.E., F.G., and P.B. contributed to data collection, analysis, and interpretation; and critically reviewed the manuscript. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Pablo Bartolucci, Unité des Maladies Génétiques du Gobule Rouge (UMGGR), CHU Henri-Mondor, 51 av du Mal de Lattre de Tassigny, Créteil Cédex, France; pablo.bartolucci@aphp.fr. 12 DECEMBER 2017 x VOLUME 1, NUMBER 26 BRAIN LESIONS IN ADULTS WITH HOMOZYGOUS SCD 2507
6 References 1. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W; Cooperative Study of Sickle Cell Disease. Mortality in children and adolescents with sickle cell disease. Pediatrics. 1989;84(3): Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. NEnglJMed. 1994; 330(23): Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1): Switzer JA, Hess DC, Nichols FT, Adams RJ. Pathophysiology and treatment of stroke in sickle-cell disease: present and future. Lancet Neurol. 2006;5(6): Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339(1): Hindmarsh PC, Brozovic M, Brook CG, Davies SC. Incidence of overt and covert neurological damage in children with sickle cell disease. Postgrad Med J. 1987;63(743): Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol. 1996;17(5): DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012;119(16): DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7): Wang W, Enos L, Gallagher D, et al; Cooperative Study of Sickle Cell Disease. Neuropsychologic performance in school-aged children with sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139(3): Armstrong FD, Thompson RJ Jr, Wang W, et al; Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Pediatrics. 1996;97(6 Pt 1): Bernaudin F, Verlhac S, Fréard F, et al. Multicenter prospective study of children with sickle cell disease: radiographic and psychometric correlation. J Child Neurol. 2000;15(5): Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR. Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology. 2001;56(8): Thangarajh M, Yang G, Fuchs D, et al. Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phosphate dehydrogenase mutation in children with sickle cell anaemia. Br J Haematol. 2012;159(3): Kinney TR, Sleeper LA, Wang WC, et al; The Cooperative Study of Sickle Cell Disease. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 1999;103(3): DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014; 371(8): Steinberg MH. More blood for sickle cell anemia? N Engl J Med. 2014;371(8): Abboud MR, Yim E, Musallam KM, Adams RJ; STOP II Study Investigators. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011;118(4): Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3): Bernaudin F, Verlhac S, Arnaud C, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood. 2011;117(4): , quiz Sutton M, Bouhassira EE, Nagel RL. Polymerase chain reaction amplification applied to the determination of beta-like globin gene cluster haplotypes. Am J Hematol. 1989;32(1): Wahlund LO, Barkhof F, Fazekas F, et al; European Task Force on Age-Related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32(6): Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; Bernaudin F, Verlhac S, Arnaud C, et al. Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia. Blood. 2015;125(10): Kwiatkowski JL, Zimmerman RA, Pollock AN, et al. Silent infarcts in young children with sickle cell disease. Br J Haematol. 2009;146(3): Wang WC, Langston JW, Steen RG, et al. Abnormalities of the central nervous system in very young children with sickle cell anemia. J Pediatr. 1998;132(6): Wang WC, Pavlakis SG, Helton KJ, et al; BABY HUG Investigators. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer. 2008;51(5): Kassim AA, Pruthi S, Day M, et al. Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia. Blood. 2016; 127(16): CALVET et al 12 DECEMBER 2017 x VOLUME 1, NUMBER 26
7 29. Pegelow CH, Macklin EA, Moser FG, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99(8): King AA, Strouse JJ, Rodeghier MJ, et al. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014; 89(2): King AA, Rodeghier MJ, Panepinto JA, et al. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014;89(10):E188-E Miller ST, Macklin EA, Pegelow CH, et al; Cooperative Study of Sickle Cell Disease. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr. 2001;139(3): Maier-Redelsperger M, Noguchi CT, de Montalembert M, et al. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood. 1994;84(9): Goldberg MA, Husson MA, Bunn HF. Participation of hemoglobins A and F in polymerization of sickle hemoglobin. J Biol Chem. 1977;252(10): Sunshine HR, Hofrichter J, Eaton WA. Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins. J Mol Biol. 1979; 133(4): Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63(4): Noguchi CT, Rodgers GP, Schechter AN. Intracellular polymerization. Disease severity and therapeutic predictions. Ann N Y Acad Sci. 1989; 565: Kobayashi S, Ikeda T, Moriya H, Ohtake T, Kumagai H. Asymptomatic cerebral lacunae in patients with chronic kidney disease. Am J Kidney Dis. 2004;44(1): Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost. 2010;8(1): Zafeirou DI, Prengler M, Gombakis N, et al. Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia. Ann Neurol. 2004;55(6): Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1): Bartolucci P, Brugnara C, Teixeira-Pinto A, et al. Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis. Blood. 2012;120(15): de Leeuw FE, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125(Pt 4): Ranque B, Menet A, Boutouyrie P, et al. Arterial stiffness impairment in sickle cell disease associated with chronic vascular complications: the multinational African CADRE study. Circulation. 2016;134(13): Charache S, Terrin ML, Moore RD, et al; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20): Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-tcd With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019): Bernaudin F, Verlhac S, Arnaud C, et al. Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities. Blood. 2016;127(14): Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13): Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12): DECEMBER 2017 x VOLUME 1, NUMBER 26 BRAIN LESIONS IN ADULTS WITH HOMOZYGOUS SCD 2509
4. STROKE AND NEUROLOGICAL COMPLICATIONS. Introduction. A. Management of Stroke in Children with Sickle Cell Disease. Principles.
4. STROKE AND NEUROLOGICAL COMPLICATIONS Introduction Patients with sickle cell disease (SCD) may be affected by various disorders of the central nervous system, including ischemic and hemorrhagic stroke,
More informationSicle-cell disease and silent cerebral infarcts evaluated with magnetic resonance imaging
Sicle-cell disease and silent cerebral infarcts evaluated with magnetic resonance imaging Poster No.: C-0243 Congress: ECR 2015 Type: Educational Exhibit Authors: E. Solomou, A. Rigopoulou, P. Kraniotis,
More informationPediatric Red Cell Exchange Indications, Benefits, Barriers. View from California Saturday May 9 th ASFA 2015
Pediatric Red Cell Exchange Indications, Benefits, Barriers View from California Saturday May 9 th ASFA 2015 Red Cell Exchange: Not SCD Recommendations for Red Cell Exchange Indication Procedure Recommendation
More informationHealth Maintenance and Education for Children and Adults
Health Maintenance and Education for Children and Adults Richard Ward, MSc, MRCP, FRCPath Director, Red Blood Cell Disorders Program, UHN Assistant Professor, Hematology, University of Toronto Chair, Canadian
More informationCorrelation between the MRI extent of silent cerebral infarcts(scis) in adult sickle-cell disease(scd) patients and the clinical severity of disease
Correlation between the MRI extent of silent cerebral infarcts(scis) in adult sickle-cell disease(scd) patients and the clinical severity of disease Poster No.: C-0451 Congress: ECR 2013 Type: Authors:
More informationSpecial Report. Toward a Stroke-Free Childhood in Sickle Cell Disease The 2013 Sherman Lecture. Robert J. Adams, MD
Special Report Toward a Stroke-Free Childhood in Sickle Cell Disease The 2013 Sherman Lecture Robert J. Adams, MD Stroke in childhood is not common outside of congenital heart disease and a few other conditions
More informationHydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease
Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease A Pocket Guide for the Clinician Susan E. Creary, MD, MSc 1 John J. Strouse, MD, PhD 2 1 The Ohio State University School of
More informationSickle Cell Anemia (SCA)
Sickle Cell Anemia (SCA) Background: Transcranial Doppler (TCD) is used to detect children with sickle cell anemia (SCA) who are at risk for stroke, and transfusion programs significantly reduce stroke
More informationHydroxurea: A Novel Approach to Optimizing the Health of Pediatric Patients with Sickle Cell Disease. Maa Ohui Quarmyne September 9 th, 2017
Hydroxurea: A Novel Approach to Optimizing the Health of Pediatric Patients with Sickle Cell Disease Maa Ohui Quarmyne September 9 th, 2017 Outline Sickle Cell Disease Pathophysiology and Clinical Manifestations
More informationThe Effect of Hydroxyurea on Vasculopathy in a Child with Sickle Cell Disease
AJNR Am J Neuroradiol 23:1692 1696, November/December 2002 Case Report The Effect of Hydroxyurea on Vasculopathy in a Child with Sickle Cell Disease Kathleen J. Helton, Winfred C. Wang, Lynn W. Wynn, Raja
More informationOriginal Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with
1 1 2 3 Original Research Article Ssafety and efficacy of prolonged hydroxycarbamide administration in adults with sickle cell disease in Northwestern Greece 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
More informationMichael R. DeBaun 1 and Allison A. King American Society of Hematology SICKLE CELL DISEASE: CLINICAL MANAGEMENT
SICKLE CELL DISEASE: CLINICAL MANAGEMENT Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative
More informationStroke occurs in 11% of children with sickle cell disease
Brain Magnetic Resonance Imaging Abnormalities in Adult Patients With Sickle Cell Disease Correlation With Transcranial Doppler Findings Gisele Sampaio Silva, MD, PhD; Perla Vicari, MD, PhD; Maria Stella
More informationHU: Myths and Facts. Melanie Kirby Associate Professor of Paediatrics
HU: Myths and Facts Melanie Kirby Associate Professor of Paediatrics SACGO Hamilton, Ontario March 5, 2016 Declaration of Disclosure I have no actual or potential conflict of interest in relation to this
More informationVasculopathie cérébrale après greffe S. VERLHAC Washington 2007
CEREBRAL VASCULOPATHY OUTCOME AFTER STEM-CELL TRANSPLANTATION FOR SICKLE CELL DISEASE S Verlhac*, F Bernaudin, C Galeotti, M Benkerrou, I Thuret, M de Montalembert, t A Kandem, M Vasile, G Sebag and the
More informationGenetic Modifiers of Sickle Cell Disease Severity. Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University
Genetic Modifiers of Sickle Cell Disease Severity Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University Outline Hb Molecule and Genetic control of globin synthesis Pathophysiology
More informationSICKLE CELL DISEASE TO TREAT OR
SICKLE CELL DISEASE TO TREAT OR NOT TO TREAT COHEM Barcelona September 8, 2012 Sujit Sheth, M.D. Pediatric Hematology Oncology Disclosures None Outline Morbidity and mortality Definitive therapies Risk
More informationHigh Hemoglobin F in a Saudi Child Presenting with Pancytopenia
Case Report imedpub Journals http://www.imedpub.com Journal of Pediatric Care ISSN 2471-805X DOI: 10.21767/2471-805X.100002 High Hemoglobin F in a Saudi Child Presenting with Pancytopenia Abstract Saudi
More informationAcute Complications of Sickle Cell Disease Case Study 5 year old girl with Hemoglobin SS, weakness and slurred speech
Acute Complications of Sickle Cell Disease Case Study 5 year old girl with Hemoglobin SS, weakness and slurred speech Beatrice E. Gee, MD Medical Director, Sickle Cell and Hematology Program Children s
More informationPRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans
PRESERVE: How intensively should we treat blood pressure in established cerebral small vessel disease? Guide to assessing MRI scans Inclusion Criteria Clinical syndrome Patients must have clinical evidence
More informationCongenital Haemoglobinopathies
Congenital Haemoglobinopathies L. DEDEKEN, MD H O P I T A L U N I V E R S I T A I R E D E S E N F A N T S R E I N E F A B I O L A U N I V E R S I T E L I B R E DE B R U X E L L E S Red Blood Cell Disorders
More informationHbSC disease is it different and how should we manage it? David Rees Department of Paediatric Haematology, King s College Hospital, London
HbSC disease is it different and how should we manage it? David Rees Department of Paediatric Haematology, King s College Hospital, London Different types of sickle cell disesease Severe sickle cell disease
More informationSickle cell disease. Fareed Omar 10 March 2018
Sickle cell disease Fareed Omar 10 March 2018 Physiology Haemoglobin structure HbA2: 2α and 2δ chains (2-3%) HbF: 2α and 2γ chains (
More informationPredictors of Cerebral Blood Flow Velocity in Children with Sickle Cell Anaemia in Lagos State, Nigeria
Predictors of Cerebral Blood Flow Velocity in Children with Sickle Cell Anaemia in Lagos State, Nigeria Motunrayo Oluwabukola Adekunle 1*, Ijeoma Nnenna Diaku-Akinwumi 1, Adeola Barakat Animasahun 1, Olisamedua
More informationNew England Pediatric Sickle Cell Consortium
New England Pediatric Sickle Cell Consortium Use of Hydroxyurea in Pediatric Patients with Sickle Cell Disease Prepared by: Kathleen Ryan, RN, MPH, and Matthew Heeney, MD. Reviewed by: New England Pediatric
More informationSickle cell disease (SCD) is understood on a genetic and a molecular level better than most diseases.
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD ig Strokes in Small Persons Robert J. Adams, MS, MD Sickle cell disease (SCD) is understood on a genetic and a molecular level better than most
More informationSickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing?
Sickle Cell Disease Why Is A Simple Genetic Disorder So Hard To Treat And How Are We Doing? James R. Eckman, MD Professor of Medicine, Hematology and Oncology Winship Cancer Institute Emory University
More informationHydroxyurea (Hydroxycarbamide) - Guidelines for treating children with Sickle Cell Disease
Hydroxyurea (Hydroxycarbamide) - Guidelines for treating children with Sickle Cell Disease Document Information Version: 2 Date: July 2014 Authors (incl. job title): Dr Moira Dick Consultant Paediatrician
More informationLong Term Effects of Hydroxyurea on Adult Patients with Sickle Cell Anemia
St. Catherine University SOPHIA Master of Arts in Nursing Theses Nursing 12-2012 Long Term Effects of Hydroxyurea on Adult Patients with Sickle Cell Anemia Christine R. Reimer St. Catherine University
More informationStrokes in children with sickle cell disease at the National Hospital Abuja Nigeria
Niger J Paed ; (): 8 6 Oniyangi O Ahmed P Otuneye OT Okon J Aikhionbare HA Olatunji OO Akano AO ORIGINAL Strokes in children with sickle cell disease at the National Hospital Abuja Nigeria DOI:http://dx.doi.org/./njp.vi,
More informationBrain tissue and white matter lesion volume analysis in diabetes mellitus type 2
Brain tissue and white matter lesion volume analysis in diabetes mellitus type 2 C. Jongen J. van der Grond L.J. Kappelle G.J. Biessels M.A. Viergever J.P.W. Pluim On behalf of the Utrecht Diabetic Encephalopathy
More informationSICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN
SICKLE CELL DISEASE Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN Objective: The student should be able: To identify the presentation, diagnosis,
More informationIs there a rationale for treatment of sickle cell anemia, except for acute complications?
Is there a rationale for treatment of sickle cell anemia, NO, but JL Vives Corrons Red Cell Pathology Unit Hospital Clnic. University of Barcelona Head of ENERCA Project EUROPEAN NETWORK FOR RARE AND CONGENITAL
More informationMinimal doses of hydroxyurea for sickle cell disease
Brazilian Journal of Medical and Biological Research (1997) 30: 933-940 Minimal HU doses for sickle cell disease ISSN 00-79X 933 Minimal doses of hydroxyurea for sickle cell disease C.S.P. Lima, V.R. Arruda,
More informationGenetic Modulation on the Phenotypic Diversity of Sickle Cell Disease
Genetic Modulation on the Phenotypic Diversity of Sickle Cell Disease Malay B. Mukherjee Abstract Sickle cell hemoglobin is a β chain structural variant where valine is substituted for glutamic acid in
More informationRedgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on
6. Imaging in TIA 6.1 What type of brain imaging should be used in suspected TIA? 6.2 Which patients with suspected TIA should be referred for urgent brain imaging? Evidence Tables IMAG1: After TIA/minor
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More information* 14.2 CHAPTER 14. Haematopoietic stem cell transplantation. In patients with sickle cell anaemia. Françoise Bernaudin, Eliane Gluckman
IRON2009_CAP.14.2(378-389):EBMT2008 4-12-2009 16:30 Pagina 378 * CHAPTER 14 Haematopoietic stem cell transplantation * 14.2 In patients with sickle cell anaemia Françoise Bernaudin, Eliane Gluckman IRON2009_CAP.14.2(378-389):EBMT2008
More informationAnemia s. Troy Lund MSMS PhD MD
Anemia s Troy Lund MSMS PhD MD lundx072@umn.edu Hemoglobinopathy/Anemia IOM take home points. 1. How do we identify the condtion? Smear, CBC Solubility Test (SCD) 2. How does it present clincally? 3. How
More informationStroke in adults with Sickle Cell Disease
Stroke in adults with Sickle Cell Disease Dr Paul Holmes Consultant Neurologist Guy s and St Thomas Hospitals Stroke and SCD Children and adults with SCA (haemoglobin SS) have a high prevalence (4.01%)
More informationSickle-Cell Disease Contributes to Cognitive Impairment in Children
Page 1 of 8 A Journal of Undergraduate Writing Sickle-Cell Disease Contributes to Cognitive Impairment in Children Acacia C. Grimes Acacia is from St. Louis, MO and graduated from MIZZOU with a bachelor
More informationStroke in Sickle Cell Disease, Risk Factors Comparative Study
American Journal of Medicine and Medical Sciences 2016, 6(1): 16-22 DOI: 10.5923/j.ajmms.20160601.03 Stroke in Sickle Cell Disease, Risk Factors Comparative Study Elan Hadi Hasan 1,*, Talib Abduljaleel
More informationSickle Cell Disease. Edward Malters, MD
Sickle Cell Disease Edward Malters, MD Introduction Vaso-occlusive phenomena and hemolysis are the clinical hallmarks of Sickle Cell Disease (SCD) Inherited disorder due to homozygosity for the abnormal
More informationManagement of Sickle Cell Disease
Management of Sickle Cell Disease A.Ferster HUDERF-ULB 29 th BHS meeting Friday 31 January 2014 Introduction > 200.000 affected births each year 2000 births in US 15 births/y in Belgium 80.000 Pts in US
More informationHistoric and Current Complications in Children with Sickle Cell Disease
Historic and Current Complications in Children with Sickle Cell Disease Trish McMahon Peterson RN, MSN, CPNP Thomas C. Hofstra MD Children's Hospital Los Angeles Comprehensive Sickle Cell Program Children's
More informationIschemic Stroke in Critically Ill Patients with Malignancy
Ischemic Stroke in Critically Ill Patients with Malignancy Jeong-Am Ryu 1, Oh Young Bang 2, Daesang Lee 1, Jinkyeong Park 1, Jeong Hoon Yang 1, Gee Young Suh 1, Joongbum Cho 1, Chi Ryang Chung 1, Chi-Min
More informationCT and MR Imaging in Young Stroke Patients
CT and MR Imaging in Young Stroke Patients Ashfaq A. Razzaq,Behram A. Khan,Shahid Baig ( Department of Neurology, Aga Khan University Hospital, Karachi. ) Abstract Pages with reference to book, From 66
More informationHydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort
Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort Maa-Ohui Quarmyne, Emory University Wei Dong, Connance, Inc Rodney Theodore,
More informationCOEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE?
COEXISTENCE OF β-thalassemia AND POLYCYTHEMIA VERA: A CHICKEN-AND-EGG DEBATE? M. DE SLOOVERE (1), L. HARLET (2), S. VAN STEENWEGHEN (3), E. MOREAU (1), D. DE SMET (1) (1) DEPARTMENT OF LABORATORY MEDICINE,
More informationHydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model
Published Ahead of Print on April 7, 2010, as doi:10.3324/haematol.2010.023325. Copyright 2010 Ferrata Storti Foundation. Early Release Paper Hydroxyurea therapy requires HbF induction for clinical benefit
More informationMagnetic resonance imaging, image analysis:visual scoring of white matter
Supplemental method ULSAM Magnetic resonance imaging, image analysis:visual scoring of white matter hyperintensities (WMHI) was performed by a neuroradiologist using a PACS system blinded of baseline data.
More informationNatural History Of Tricuspid Regurgitant Jet Velocity And A New Association With Proteinuria In Children With Sickle Cell Disease
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2013 Natural History Of Tricuspid Regurgitant Jet Velocity
More informationHemolytic anemias (2 of 2)
Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy Mutation in the β-globin
More informationDependance on chronic transfusion
Dependance on chronic transfusion Pr Saliou Diop Hematology Blood transfusion Dakar- Sénégal diop@cnts-dakar.sn Introduction Chronic transfusion: Regular use of blood transfusion in patients with chronic
More informationHydroxyurea. for Sickle Cell Disease. A Guide for Starting Treatment. Hydroxyurea is a medicine proven to prevent pain from sickle cell disease.
Hydroxyurea for Sickle Cell Disease A Guide for Starting Treatment Hydroxyurea is a medicine proven to prevent pain from sickle cell disease. This handbook was created to help answer common questions about
More informationY Issa 1, JK Mwansa 2, G Mwikuma 3, S Siziya 4
RESEARCH REPORT Clinical picture and correlates for sickle cell anaemia among Zambian children attending Arthur Davison Children s Hospital Sickle Cell Disease clinic in Zambia Y Issa 1, JK Mwansa 2, G
More informationInterleukin-1ß and Interleukin-6 Genetic Polymorphisms and Sickle Cell Disease: An Egyptian Study
Interleukin-1ß and Interleukin-6 Genetic Polymorphisms and Sickle Cell Disease: An Egyptian Study MONA EL-GHAMRAWY, MD, PROFESSOR OF PEDIATRICS & PEDIATRIC HEMATOLOGY, CAIRO UNIVERSITY melghamrawy95@gmail.com
More informationThe Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
More informationCentral Nervous System Complications and Management in Sickle Cell Disease:
Central Nervous System Complications and Management in Sickle Cell Disease: A Review Michael R. DeBaun MD, MPH 1 and Fenella J. Kirkham, MD 2 1 Department of Pediatrics and Medicine, Division of Hematology/Oncology,
More informationRationale for RBC Transfusion in SCD
Rationale for RBC Transfusion in SCD Dilution of HgbS-containing RBCs via the addition of HgbA-containing cells from the blood of normal donors Suppression of erythropoietin release caused by the rise
More informationVascular Malformations of the Brain: A Review of Imaging Features and Risks
Vascular Malformations of the Brain: A Review of Imaging Features and Risks Comprehensive Neuroradiology: Best Practices October 27-30, 2016 Sudhakar R. Satti, MD Associate Director Neurointerventional
More informationHydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know
614962JPOXXX10.1177/1043454215614962Journal of Pediatric Oncology NursingRees research-article2015 Article Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know Journal of
More informationCost-effectiveness of hydroxyurea in sickle cell anemia Moore R D, Charache S, Terrin M L, Barton F B, Ballas S K
Cost-effectiveness of hydroxyurea in sickle cell anemia Moore R D, Charache S, Terrin M L, Barton F B, Ballas S K Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationSickle cell disease (SCD) was first described almost
SICKLE CELL DISEASE Advances in the use of hydroxyurea Russell E. Ware 1 and Banu Aygun 1 1 Department of Hematology, St. Jude Children s Research Hospital, Memphis TN Clinical experience with hydroxyurea
More informationMaking Hope A Reality December 10, Nasdaq : BLUE
Making Hope A Reality December 10, 2014 Nasdaq : BLUE Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words
More informationA bout 170 babies are born annually in the UK with sickle
325 Coping and health service utilisation in a UK study of paediatric sickle cell pain K A Anie, A Steptoe, S Ball, M Dick, B M Smalling... Seeletteronp385 See end of article for authors affiliations...
More informationDisclosure. Presented analysis part of larger study funded by Terumo BCT
1 Comparison of Transfusion Adverse Events in Children with Sickle Cell Disease (SCD) Receiving or Automated Red Blood Cell Exchange (arbx) Transfusions for Stroke Prevention Shannon Kelly, M.D. 2 Disclosure
More information1 MS Lesions in T2-Weighted Images
1 MS Lesions in T2-Weighted Images M.A. Sahraian, E.-W. Radue 1.1 Introduction Multiple hyperintense lesions on T2- and PDweighted sequences are the characteristic magnetic resonance imaging (MRI) appearance
More informationEmbolic Protection Devices for Transcatheter Aortic Valve Replacement
Embolic Protection Devices for Transcatheter Aortic Valve Replacement James M. McCabe, MD Medical Director, Cardiac Cath Lab University of Washington Seattle, WA Disclosures Proctoring and honoraria for
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35456 holds various files of this Leiden University dissertation. Author: Hassan, Suha Mustafa Title: Toward prevention of Hemoglobinopathies in Oman Issue
More informationCHANGING MEDICINE. CHANGING LIVES THE POWER OF CLINICAL RESEARCH
CHANGING MEDICINE. CHANGING LIVE THE POWER OF CLINICAL REEARCH CAGO Learning for Life, eptember 2016 Rebecca Leroux RN, BcN, CCRP Red Blood Cell Disorders Program, University Health Network Manuela Merelles-Pulcini
More informationHydroxyurea (Hydroxycarbamide) - Guidelines for treating children with Sickle Cell Disease
Hydroxyurea (Hydroxycarbamide) - Guidelines for treating children with Sickle Cell Disease Patient selection The benefits of hydroxycarbamide should be discussed with all parents/carers of children with
More informationDONE BY : RaSHA RAKAN & Bushra Saleem
DONE BY : RaSHA RAKAN & Bushra Saleem Hemolytic anemias (2 of 2) Sickle Cell Anemia The most common familial hemolytic anemia in the world Sickle cell anemia is the prototypical (and most prevalent) hemoglobinopathy
More informationBridging the Gap: Improving Sickle Cell Disease Transition from Pediatric- to Adult-Focused Care ASFA 2017 Annual Meeting
Bridging the Gap: Improving Sickle Cell Disease Transition from Pediatric- to Adult-Focused Care ASFA 2017 Annual Meeting Kim Smith-Whitley, MD Director Comprehensive Sickle Cell Center The Children s
More informationAPOL1, a-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia
APOL1, a-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia Sickle cell anemia (SCA) is caused by a mutation in the β-globin gene
More informationGuideline for the Acute Management of Stroke in Paediatric Patients with Sickle Cell Disease
Guideline for the Acute Management of Stroke in Paediatric Patients with Sickle Cell Disease Summary Outline of the presentation of stroke in paediatric patients with sickle cell disease, urgent investigations,
More informationDeveloping Cardiac Screening Guidelines for Children with Sickle Cell Disease
Jamie Harrington CRC IRB Proposal August 2, 2012 Developing Cardiac Screening Guidelines for Children with Sickle Cell Disease A. Study Purpose and Rationale Sickle cell disease (SCD) is a genetic erythrocyte
More informationDisease severity and slower psychomotor speed in adults with sickle cell disease
REGULAR ARTICLE Disease severity and slower psychomotor speed in adults with sickle cell disease Dana R. Jorgensen, 1 Andrea Metti, 1 Meryl A. Butters, 2 Joseph M. Mettenburg, 3 Caterina Rosano, 1 and
More informationHow to Write a Life Care Plan for a Child with Hemoglobinopathy
How to Write a Life Care Plan for a Child with Hemoglobinopathy Tamar Fleischer, BSN, MSN, CNLCP & Mona Yudkoff, RN, MPH, CRRN, CNLCP BalaCare Solutions March 2018 St. Peterburg, Florida What is Hemoglobinopathy?
More informationAnatomical variations of the circle of Willis and cerebrovascular accidents in transitional Albania
ORIGINAL RESEARCH Anatomical variations of the circle of Willis and cerebrovascular accidents in transitional Albania Edlira Harizi (Shemsi) 1,2, Arben Rroji 3, Elton Cekaj 1, Sazan Gabrani 2 1 Regional
More information10/19/12. Uncommon Causes of Stroke. José Biller, MD, FACP, FAAN, FAHA Disclosures. Dr. Biller has no disclosures to report
10/19/12 Uncommon Causes of Stroke José Biller, MD, FACP, FAAN, FAHA Loyola University Chicago Stritch School of Medicine Chicago, IL José Biller, MD, FACP, FAAN, FAHA Disclosures Dr. Biller has no disclosures
More informationAcute vaso-occlusive Pain in children
Acute vaso-occlusive Pain in children Dr François Angoulvant 1 Dr Sebastien Redant 2 Dr Malika Benkerrou 1 Pr Alina Ferster 2 Hôpital Robert Debré - Paris Hôpital des Enfants Reine Fabiola Bruxelles Réseau
More informationNeuropsychological Assessment, Neuroimaging, and Neuropsychiatric Evaluation in Pediatric and Adult Patients with Sickle Cell Disease (SCD)
Neuropsychological Assessment, Neuroimaging, and Neuropsychiatric Evaluation in Pediatric and Adult Patients with Sickle Cell Disease (SCD) The Harvard community has made this article openly available.
More informationStroke: Guidelines for In-patient Management in Children with Sickle Cell Disease
Version 02 Approved by Inter-professional Patient Care Committee: December 2, 2016 1.0 Introduction Target Users: Clinicians managing patients with Sickle Cell Disease who present acutely with a change
More informationThalassemias:general aspects and molecular pathology
Thalassemias:general aspects and molecular pathology Prof. Renzo Galanello Pediatric Clinic 2 University of Cagliari Ospedale Regionale Microcitemie-ASL8 HEMOGLOBINOPATHIES CLASSIFICATION Structurally
More informationUvA-DARE (Digital Academic Repository)
UvA-DARE (Digital Academic Repository) Mind matters in pediatric sickle cell disease: evaluation of neurocognitive deficits, behavioral and emotional problems and health-related quality of life Hijmans,
More informationArterial Spin Labeling Measurement of Cerebral Perfusion in Children With Sickle Cell Disease
CME JOURNAL OF MAGNETIC RESONANCE IMAGING 35:779 787 (2012) Original Research Arterial Spin Labeling Measurement of Cerebral Perfusion in Children With Sickle Cell Disease Sanna Gevers, MD, 1 * Aart J.
More informationAPOL1, Alpha thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia
Published Ahead of Print on September 22, 2016, as doi:10.3324/haematol.2016.154153. Copyright 2016 Ferrata Storti Foundation. APOL1, Alpha thalassemia, and BCL11A variants as a genetic risk profile for
More informationUnraveling Hemoglobinopathies with Capillary Electrophoresis
Session Number 2002 Unraveling Hemoglobinopathies with Capillary Electrophoresis David F. Keren, M.D. Professor of Pathology Division Director, Clinical Pathology The University of Michigan dkeren@med.umich.edu
More informationIn cerebral infarction, the prognostic value of angiographic
Nonrelevant Cerebral Atherosclerosis is a Strong Prognostic Factor in Acute Cerebral Infarction Jinkwon Kim, MD; Tae-Jin Song, MD; Dongbeom Song, MD; Hye Sun Lee, MS; Chung Mo Nam, PhD; Hyo Suk Nam, MD,
More information[(PHY-3a) Initials of MD reviewing films] [(PHY-3b) Initials of 2 nd opinion MD]
2015 PHYSICIAN SIGN-OFF (1) STUDY NO (PHY-1) CASE, PER PHYSICIAN REVIEW 1=yes 2=no [strictly meets case definition] (PHY-1a) CASE, IN PHYSICIAN S OPINION 1=yes 2=no (PHY-2) (PHY-3) [based on all available
More informationSilent Infarction in Patients with First-ever Stroke
221 Silent Infarction in Patients with First-ever Stroke Cheung-Ter Ong 1, Wen-Pin Chen 2, Sheng-Feng Sung 1, Chi-Shun Wu 1, and Yung-Chu Hsu 1 Abstract- Background / Purpose: Silent infarcts (SIs) are
More informationAcute Chest Syndrome: Can a Chest Radiograph Predict the Course Severity of the Disease?
Original Article Elmer Press Acute Chest Syndrome: Can a Chest Radiograph Predict the Course Severity of the Disease? Arie Franco a, c, Kathleen Tarrant McKie b, Patrick Ryan Henderson a, Kristopher Neal
More informationDelayed hemolytic transfusion reaction in the French hemovigilance system
Delayed hemolytic transfusion reaction in the French hemovigilance system C. Rieux, G. Brittenham, D. Bachir, E. De Meyer, K. Boudjedir for the French hemovigilance network First Seminar on delayed hemolytic
More informationCorrelation of Neurodevelopmental Outcome and brain MRI/EEG findings in term HIE infants
Correlation of Neurodevelopmental Outcome and brain MRI/EEG findings in term HIE infants Ajou University School of Medicine Department of Pediatrics Moon Sung Park M.D. Hee Cheol Jo, M.D., Jang Hoon Lee,
More informationNewborn Screening for Sickle Cell Disease in Africa: Public health meets reality
13 th September 2016 Newborn Screening for Sickle Cell Disease in Africa: Public health meets reality Kwaku Ohene-Frempong. MD Children s Hospital of Philadelphia Sickle Cell Foundation of Ghana Disclosure
More informationHydroxycarbamide. Sickle and Thalassaemia Training days. September Dr Sara Stuart-Smith. Why do sickle cells cause pain and organ damage?
Sickle and Thalassaemia Training days September 2017 Hydroxycarbamide Dr Sara Stuart-Smith Why do sickle cells cause pain and organ damage? Under certain conditions, haemoglobin S forms long rigid strands
More informationArterial Stiffness and Early Vascular Aging
International Post-Graduation Program Arterial Stiffness and Early Vascular Aging 4th Edition 18th - 19 th November, 2015. Center for the Research and Treatment of Arterial Hypertension and Cardiovascular
More informationA common clinical dilemma. Ischaemic stroke or TIA with atrial fibrillation MRI scan with blood-sensitive imaging shows cerebral microbleeds
Cerebral microbleeds and intracranial haemorrhage risk in patients with atrial fibrillation after acute ischaemic stroke or transient ischaemic attack: multicentre observational cohort study D. Wilson,
More informationHematological profile among Sudanese patients with sickle cell anemia
EUROPEAN ACADEMIC RESEARCH Vol. III, Issue 4/ July 2015 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Hematological profile among Sudanese patients with sickle cell
More information